Lasse Pihlstrøm

Lasse Pihlstrøm is a Professor II at the Department of Neurology, Faculty of Medicine, University of Oslo, and Oslo University Hospital (OUS), Rikshospitalet. He maintains a dual affiliation with the Department of Radiology and Nuclear Medicine, reflecting the interdisciplinary nature of his work in neurodegenerative disorders. His research bridges clinical neurology with advanced genetic and molecular methodologies to unravel the complexities of Parkinson's disease and related conditions.

Dr. Pihlstrøm's research interests center on Parkinson's disease genetics, with particular emphasis on polygenic risk scoring, epigenome-wide association studies, and the investigation of genetic modifiers of disease progression. His work spans multiple dimensions of neurodegenerative disease research, including ancestral diversity in genetic risk, sex-specific differences, lysosomal function in neurodegeneration, and the intersection between Parkinson's disease and other conditions like Alzheimer's disease and cancer. His laboratory employs cutting-edge genomic, epigenomic, and transcriptomic approaches to identify disease mechanisms and potential therapeutic targets.

Analysis of his recent publication record reveals a clear trajectory toward integrative multi-omics approaches that combine genetic, epigenetic, and transcriptomic data to understand Parkinson's disease mechanisms. His work increasingly focuses on cross-disease comparisons, population diversity, and the development of predictive models for disease risk and progression. Notably, his research demonstrates strong international collaboration through large consortia such as COURAGE-PD.

• Kavlipris to four pioneers in neurogenetics (2022)

Dr. Pihlstrøm actively participates in major international research consortia focused on Parkinson's disease genetics and neurodegeneration. His work has been instrumental in advancing our understanding of the genetic architecture of Parkinson's disease across diverse populations. Through his leadership in projects like the COURAGE-PD Consortium, he has contributed significantly to identifying genetic determinants of disease onset, progression, and clinical manifestations. His research has important implications for developing personalized approaches to Parkinson's disease diagnosis and treatment.